$107.89
1.69% yesterday
Nasdaq, Apr 03, 10:00 pm CET
ISIN
US05464T1043
Symbol
AXSM
Sector
Industry

Axsome Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Axsome Therapeutics, Inc. Classifications & Recommendation:

Buy
100%

Axsome Therapeutics, Inc. Price Target

Target Price $176.63
Price $107.89
Potential
Number of Estimates 17
17 Analysts have issued a price target Axsome Therapeutics, Inc. 2026 . The average Axsome Therapeutics, Inc. target price is $176.63. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 17 Analysts recommend Axsome Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Axsome Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Axsome Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 385.69 620.50
42.53% 60.88%
EBITDA Margin -63.39% -15.56%
2.58% 75.45%
Net Margin -75.59% -21.69%
20.25% 71.30%

16 Analysts have issued a sales forecast Axsome Therapeutics, Inc. 2025 . The average Axsome Therapeutics, Inc. sales estimate is

$621m
Unlock
. This is
60.88% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$686m 77.98%
Unlock
, the lowest is
$559m 44.94%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $386m 42.53%
2025
$621m 60.88%
Unlock
2026
$1.0b 64.18%
Unlock
2027
$1.5b 51.08%
Unlock
2028
$2.1b 38.27%
Unlock
2029
$2.7b 26.65%
Unlock

4 Analysts have issued an Axsome Therapeutics, Inc. EBITDA forecast 2025. The average Axsome Therapeutics, Inc. EBITDA estimate is

$-96.6m
Unlock
. This is
60.53% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$16.4m 106.70%
Unlock
, the lowest is
$-220m 10.18%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-244m 38.85%
2025
$-96.6m 60.50%
Unlock
2026
$204m 311.62%
Unlock
2027
$574m 180.70%
Unlock
2028
$805m 40.42%
Unlock
2029
$1.2b 49.44%
Unlock

EBITDA Margin

2024 -63.39% 2.58%
2025
-15.56% 75.45%
Unlock
2026
20.06% 228.92%
Unlock
2027
37.27% 85.79%
Unlock
2028
37.85% 1.56%
Unlock
2029
44.65% 17.97%
Unlock

8 Axsome Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Axsome Therapeutics, Inc. net profit estimate is

$-135m
Unlock
. This is
53.92% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-35.0m 88.00%
Unlock
, the lowest is
$-229m 21.60%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-292m 13.66%
2025
$-135m 53.84%
Unlock
2026
$120m 189.12%
Unlock
2027
$473m 294.36%
Unlock
2028
$802m 69.59%
Unlock
2029
$1.1b 33.14%
Unlock

Net Margin

2024 -75.59% 20.25%
2025
-21.69% 71.30%
Unlock
2026
11.77% 154.26%
Unlock
2027
30.73% 161.09%
Unlock
2028
37.68% 22.62%
Unlock
2029
39.62% 5.15%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -5.99 -2.76
13.66% 53.92%
P/E negative
EV/Sales 8.30

8 Analysts have issued a Axsome Therapeutics, Inc. forecast for earnings per share. The average Axsome Therapeutics, Inc. EPS is

$-2.76
Unlock
. This is
54.00% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.72 88.00%
Unlock
, the lowest is
$-4.70 21.67%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.99 13.66%
2025
$-2.76 53.92%
Unlock
2026
$2.46 189.13%
Unlock
2027
$9.72 295.12%
Unlock
2028
$16.48 69.55%
Unlock
2029
$21.94 33.13%
Unlock

P/E ratio

Current -18.00 17.26%
2025
-39.02 116.78%
Unlock
2026
43.79 212.22%
Unlock
2027
11.10 74.65%
Unlock
2028
6.55 40.99%
Unlock
2029
4.92 24.89%
Unlock

Based on analysts' sales estimates for 2025, the Axsome Therapeutics, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 13.35 0.91%
2025
8.30 37.84%
Unlock
2026
5.05 39.09%
Unlock
2027
3.35 33.81%
Unlock
2028
2.42 27.68%
Unlock
2029
1.91 21.04%
Unlock

P/S ratio

Current 13.64 2.36%
2025
8.48 37.84%
Unlock
2026
5.16 39.09%
Unlock
2027
3.42 33.81%
Unlock
2028
2.47 27.68%
Unlock
2029
1.95 21.04%
Unlock

Current Axsome Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Apr 03 2025
Needham
Locked
Locked
Locked Apr 01 2025
Mizuho
Locked
Locked
Locked Mar 27 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 06 2025
Needham
Locked
Locked
Locked Mar 03 2025
Baird
Locked
Locked
Locked Mar 03 2025
Morgan Stanley
Locked
Locked
Locked Feb 27 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 03 2025
Locked
Needham:
Locked
Locked
Apr 01 2025
Locked
Mizuho:
Locked
Locked
Mar 27 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 06 2025
Locked
Needham:
Locked
Locked
Mar 03 2025
Locked
Baird:
Locked
Locked
Mar 03 2025
Locked
Morgan Stanley:
Locked
Locked
Feb 27 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today